138 related articles for article (PubMed ID: 30992165)
1. Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Zhang K; Ni Y; Chen J; Tu Z; Wu X; Chen D; Yao H; Jiang S
Bioorg Med Chem Lett; 2019 Jun; 29(12):1502-1506. PubMed ID: 30992165
[TBL] [Abstract][Full Text] [Related]
2. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS
J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419
[TBL] [Abstract][Full Text] [Related]
3. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
[TBL] [Abstract][Full Text] [Related]
4. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW
J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
[TBL] [Abstract][Full Text] [Related]
6. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Fratta S; Biniecka P; Moreno-Vargas AJ; Carmona AT; Nahimana A; Duchosal MA; Piacente F; Bruzzone S; Caffa I; Nencioni A; Robina I
Eur J Med Chem; 2023 Mar; 250():115170. PubMed ID: 36787658
[TBL] [Abstract][Full Text] [Related]
11. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
12. Structure-based drug design of novel carborane-containing nicotinamide phosphoribosyltransferase inhibitors.
Asawa Y; Katsuragi K; Sato A; Yoshimori A; Tanuma SI; Nakamura H
Bioorg Med Chem; 2019 Jul; 27(13):2832-2844. PubMed ID: 31103405
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
14. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure-based comparison of two NAMPT inhibitors.
Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
[TBL] [Abstract][Full Text] [Related]
16. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Gunzner-Toste J; Liederer BM; Ly J; O'Brien T; Oh A; Wang L; Wang W; Xiao Y; Zak M; Zhao G; Yuen PW; Bair KW
J Med Chem; 2013 Aug; 56(16):6413-33. PubMed ID: 23859118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
